Properties of antitumor anthracyclines and new developments in their application: Cain memorial award lecture

scientific article

Properties of antitumor anthracyclines and new developments in their application: Cain memorial award lecture is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID3864526

P2093author name stringArcamone F
P433issue12 Pt 1
P407language of work or nameEnglishQ1860
P304page(s)5995-5999
P577publication date1985-12-01
P1433published inCancer ResearchQ326097
P1476titleProperties of antitumor anthracyclines and new developments in their application: Cain memorial award lecture
P478volume45

Reverse relations

cites work (P2860)
Q61795933A computational study of Anthracyclines interacting with lipid bilayers: Correlation of membrane insertion rates, orientation effects and localisation with cytotoxicity
Q84453578Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide
Q46897227An electron transfer approach to the preparation of highly functionalized anthraquinones
Q39734481Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties
Q42007942Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts
Q68764226Antitumor activity of new anthracycline analogues in combination with interferon alfa
Q41752579Cardiac toxicity and antitumor activity of 4'-deoxy-4'-iodo-doxorubicinol
Q68775552Comparative in vitro activity of 4'-deoxy-4'-iododoxorubicin and other anthracyclines in the human tumor clonogenic assay
Q42390506Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells
Q40488017Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy
Q50892060Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A.
Q60589833In vitro activity of 4? -iodo-4? -deoxydoxorubicin on human colo-rectal cancer as measured by a short-term antimetabolic assay
Q73701516Is the drug-responsive NADH oxidase of the cancer cell plasma membrane a molecular target for adriamycin?
Q41146888Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicin
Q54391054Lack of cross-resistance of a doxorubicin-resistant B16 melanoma line with 4'-deoxy-4'-iodo-doxorubicin
Q70244899Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans
Q39768346Pharmacokinetics of anticancer drugs in children
Q34416726Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer
Q67974060Reduced cardiotoxicity and increased cytotoxicity in a novel anthracycline analogue, 4'-amino-3'-hydroxy-doxorubicin
Q72050216Response to adriamycin of transplasma membrane electron transport in adriamycin-resistant and nonresistant HL-60 cells
Q36505025Synthesis and Anti-Platelet Activity of Thiosulfonate Derivatives Containing a Quinone Moiety
Q94089192Synthesis of 3-Alkenyl-1-azaanthraquinones Diels-Alder and Electron Transfer Reactions

Search more.